doi: 10.1016/j.foodchem.2021.129760 90 Rodrguez-BencomoJ
Tirzepatide often delivers more weight loss and deeper metabolic changes than semaglutide , which can give it an edge in antiaging protocols when the priority is clearing visceral fat while protecting muscle
So the Tesamorelin GH-IGF-1 axis still produces a real downstream signal at 12 weeks, at 26 weeks, and at 52 weeks of continuous use
While results in lab studies are promising, Tirzepatide is not approved for human or animal use and should only be used in research environments by qualified professionals
This information helps guide future adjustments and improvements in your protocol
Individual characteristics such as age, weight, overall health status, lifestyle choices, or underlying medical conditions all influence how quickly someone may experience positive results when taking semaglutide